- Home
- TYRA vs NBN Comparison
TYRA vs NBN Comparison
Compare TYRA & NBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- NBN
- Stock Information
- Founded
- TYRA 2018
- NBN 1872
- Country
- TYRA United States
- NBN United States
- Employees
- TYRA N/A
- NBN N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- NBN Major Banks
- Sector
- TYRA Health Care
- NBN Finance
- Exchange
- TYRA Nasdaq
- NBN Nasdaq
- Market Cap
- TYRA 812.7M
- NBN 753.2M
- IPO Year
- TYRA 2021
- NBN N/A
- Fundamental
- Price
- TYRA $14.00
- NBN $91.78
- Analyst Decision
- TYRA Strong Buy
- NBN Buy
- Analyst Count
- TYRA 5
- NBN 2
- Target Price
- TYRA $31.00
- NBN $91.00
- AVG Volume (30 Days)
- TYRA 219.5K
- NBN 66.2K
- Earning Date
- TYRA 11-07-2024
- NBN 01-28-2025
- Dividend Yield
- TYRA N/A
- NBN 0.04%
- EPS Growth
- TYRA N/A
- NBN 12.22
- EPS
- TYRA N/A
- NBN 7.69
- Revenue
- TYRA N/A
- NBN $157,668,000.00
- Revenue This Year
- TYRA N/A
- NBN N/A
- Revenue Next Year
- TYRA N/A
- NBN $10.37
- P/E Ratio
- TYRA N/A
- NBN $11.93
- Revenue Growth
- TYRA N/A
- NBN 16.87
- 52 Week Low
- TYRA $11.24
- NBN $49.07
- 52 Week High
- TYRA $29.60
- NBN $105.44
- Technical
- Relative Strength Index (RSI)
- TYRA 32.68
- NBN 37.01
- Support Level
- TYRA $14.65
- NBN $96.78
- Resistance Level
- TYRA $15.55
- NBN $99.50
- Average True Range (ATR)
- TYRA 0.72
- NBN 2.97
- MACD
- TYRA 0.02
- NBN -1.35
- Stochastic Oscillator
- TYRA 3.12
- NBN 7.13
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the US. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived primarily from interest and dividends from the bank.